Frovatriptan for acute treatment of migraine associated with menstruation: Results from an open-label postmarketing surveillance study

Journal of Women's Health

Volumn 18, Issue 8, 2009, Pages 1265-1273

  Newman, Lawrence C ^a   Harper, Samira ^b   Jones, Beverly A ^b   Campbell, John ^b  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^b ENDO PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FROVATRIPTAN;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; DRUG UTILIZATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MENSTRUAL MIGRAINE; NAUSEA; PAIN ASSESSMENT; PATIENT SATISFACTION; PHONOPHOBIA; PHOTOPHOBIA; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RECURRENCE RISK; TREATMENT OUTCOME; VOMITING;

ADULT; CARBAZOLES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MENSTRUATION DISTURBANCES; MIDDLE AGED; MIGRAINE DISORDERS; PAIN MEASUREMENT; PATIENT SATISFACTION; PRODUCT SURVEILLANCE, POSTMARKETING; RETROSPECTIVE STUDIES; SEROTONIN AGONISTS; TREATMENT OUTCOME; TRYPTAMINES; WOMEN'S HEALTH; YOUNG ADULT;

EID: 70349201299     PISSN: 15409996     EISSN: None     Source Type: Journal    
DOI: 10.1089/jwh.2008.1031     Document Type: Article

References (26)

1. Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007;68:343-349.
2. Leonardi M, Steiner TJ, Scher AT, Lipton RB. The global burden of migraine: Measuring disability in headache disorders with WHO's Classification of Functioning, Disability and Health (ICF). J Headache Pain 2005;6:429-440.
3. Brandes JL. Global trends in migraine care: Results from the MAZE survey. CNS Drugs 2002;16:13-18.
4. Diamond S, Bigal ME, Silberstein S, Loder E, Reed M, Lipton RB. Patterns of diagnosis and acute and preventive treatment for migraine in the United States: Results from the American Migraine Prevalence and Prevention study. Headache 2007;47:355-363.
5. Ferrari MD, Goadsby PJ, Roon KI, Lipton RB. Triptans (serotonin, 5-HT1B=1D agonists) in migraine: Detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 2002;22:633-658.
6. Dahlof CG. Infrequent or non-response to oral sumatriptan does not predict response to other triptans-Review of four trials. Cephalalgia 2006;26:98-106.
7. Diener HC, Gendolla A, Gebert I, Beneke M. Almotriptan in migraine patients who respond poorly to oral sumatriptan: A double-blind, randomized trial. Headache 2005;45:874-882. (Pubitemid 41045364)
8. Farkkila M, Olesen J, Dahlof C, et al. Eletriptan for the treatment of migraine in patients with previous poor response or tolerance to oral sumatriptan. Cephalalgia 2003;23:463-471.
9. Dzoljic E, Sipetic S, Vlajinac H, et al. Prevalence of menstrually related migraine and nonmigraine primary headache in female students of Belgrade University. Headache 2002;42:185-193.
10. Granella F, Sances G, Allais G, et al. Characteristics of menstrual and nonmenstrual attacks in women with menstrually related migraine referred to headache centres. Cephalalgia 2004;24:707-716.
11. Adeney KL, Flores JL, Perez JC, Sanchez SE, Williams MA. Prevalence and correlates of migraine among women attending a prenatal care clinic in Lima, Peru. Cephalalgia 2006;26:1089-1096.
12. Granella F, Sances G, Pucci E, Nappi RE, Ghiotto N, Napp G. Migraine with aura and reproductive life events: A case control study. Cephalalgia 2000;20:701-707.
13. Granella F, Sances G, Zanferrari C, Costa A, Martignoni E, Manzoni GC. Migraine without aura and reproductive life events: A clinical epidemiological study in 1300 women. Headache 1993;33:385-389.
14. MacGregor EA, Frith A, Ellis J, Aspinall L, Hackshaw A. Incidence of migraine relative to menstrual cycle phases of rising and falling estrogen. Neurology 2006;67:2154-2158.
15. MacGregor EA, Hackshaw A. Prevalence of migraine on each day of the natural menstrual cycle. Neurology 2004;63: 351-353.
16. Stewart WF, Lipton RB, Chee E, Sawyer J, Silberstein SD. Menstrual cycle and headache in a population sample of migraineurs. Neurology 2000;55:1517-1523.
17. Pfaffenrath V, Spierings EL. [Treatment of acute migraine attacks: Effective and economic alternative.] Nervenheilkunde 2004;23:545-548.
18. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988;8(Suppl 7):1-96.
19. Headache Classification Committee of the International Headache Society. The international classification of headache disorders, 2nd ed. Cephalalgia 2004;24(Suppl 1): 9-160.
20. Ryan R, Geraud G, Goldstein J, Cady R, Keywood C. Clinical efficacy of frovatriptan: Placebo-controlled studies. Headache 2002;42(Suppl 2):S84-92.
21. Geraud G, Keywood C, Senard JM. Migraine headache recurrence: Relationship to clinical, pharmacological, and pharmacokinetic properties of triptans. Headache 2003;43: 376-388.
22. Lipton RB, Stewart WF. Acute migraine therapy: Do doctors know what migraine patients want from therapy? Headache 1999;39:S20-S26.
23. Sheftell FD, Feleppa M, Tepper SJ, Volcy M, Rapoport AM, Bigal ME. Patterns of use of triptans and reasons for switching them in a tertiary care migraine population. Headache 2004;44:661-668.
24. MacGregor EA, Brandes J, Eikermann A. Migraine prevalence and treatment patterns: The global Migraine and Zolmitriptan Evaluation survey. Headache 2003;43:19-26.
25. MacGregor EA. "Menstrual" migraine: Towards a definition. Cephalalgia 1996;16:11-21.
26. Couturier EG, Bomhof MA, Neven AK, van Duijn NP. Menstrual migraine in a representative Dutch population sample: Prevalence, disability and treatment. Cephalalgia 2003;23:302-308.